These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35988850)

  • 21. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.
    Lozano C; Azcona-Gutiérrez JM; Van Bambeke F; Sáenz Y
    PLoS One; 2018; 13(9):e0204167. PubMed ID: 30212579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compensatory evolution of Pseudomonas aeruginosa's slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis.
    La Rosa R; Rossi E; Feist AM; Johansen HK; Molin S
    Nat Commun; 2021 May; 12(1):3186. PubMed ID: 34045458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa
    Moustafa DA; Wu AW; Zamora D; Daly SM; Sturge CR; Pybus C; Geller BL; Goldberg JB; Greenberg DE
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients.
    Greipel L; Fischer S; Klockgether J; Dorda M; Mielke S; Wiehlmann L; Cramer N; Tümmler B
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6726-6734. PubMed ID: 27572404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrolide antibiotics for cystic fibrosis.
    Southern KW; Barker PM; Solis-Moya A; Patel L
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002203. PubMed ID: 23152214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006961. PubMed ID: 18646176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in
    Jorth P; McLean K; Ratjen A; Secor PR; Bautista GE; Ravishankar S; Rezayat A; Garudathri J; Harrison JJ; Harwood RA; Penewit K; Waalkes A; Singh PK; Salipante SJ
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery?
    Tateda K; Ishii Y; Kimura S; Horikawa M; Miyairi S; Yamaguchi K
    J Infect Chemother; 2007 Dec; 13(6):357-67. PubMed ID: 18095083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa.
    Feltner JB; Wolter DJ; Pope CE; Groleau MC; Smalley NE; Greenberg EP; Mayer-Hamblett N; Burns J; Déziel E; Hoffman LR; Dandekar AA
    mBio; 2016 Oct; 7(5):. PubMed ID: 27703072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility and mechanisms of high-level macrolide resistance in clinical isolates of Moraxella nonliquefaciens.
    Nonaka S; Matsuzaki K; Kazama T; Nishiyama H; Ida Y; Koyano S; Sonobe K; Okamura N; Saito R
    J Med Microbiol; 2014 Feb; 63(Pt 2):242-247. PubMed ID: 24196134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrolide antibiotics for cystic fibrosis.
    Southern KW; Barker PM; Solis-Moya A; Patel L
    Cochrane Database Syst Rev; 2011 Dec; (12):CD002203. PubMed ID: 22161368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudomonas aeruginosa populations in the cystic fibrosis lung lose susceptibility to newly applied β-lactams within 3 days.
    Tueffers L; Barbosa C; Bobis I; Schubert S; Höppner M; Rühlemann M; Franke A; Rosenstiel P; Friedrichs A; Krenz-Weinreich A; Fickenscher H; Bewig B; Schreiber S; Schulenburg H
    J Antimicrob Chemother; 2019 Oct; 74(10):2916-2925. PubMed ID: 31355848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.